The Path to Progress: Market Access Spotlight
After Regulatory Affairs and Medical Affairs, the next stage of The Path to Progress journey is Market Access.
Once a medicine has been granted marketing authorisation and a licence - a process with close collaboration between Regulatory Affairs and Medical Affairs – the next step is to secure reimbursement, through a Health Technology Appraisal (HTA). This decides whether a medicine will be offered on the NHS and to what population of patients.
The HTA process ensures that a medicine is both beneficial to patients and economically sustainable for the healthcare system, when assessing the clinical and cost-effectiveness of the medicine against existing alternatives.
About Market Access at Bristol Myers Squibb in the UK and Ireland
Our Market Access colleagues are responsible for leading the HTA process. They span four specialisms:
- Health Economics and Outcomes Research (HEOR)
- Policy Advocacy, and Government Affairs (PAGA), and
Sophia Ho (HEOR), Alistair Monro (PAGA), and Sue Consterdine, (Partnerships), all work together as part of the Market Access team and are based at our UK Head Office, in Uxbridge.
Watch the Market Access Spotlight video below, to learn more about their roles and how the different specialisms within Market Access collaborate to make our innovative medicines available to the patients who need them.